Concepedia

Erhan Keleş

EK

Statistics

Publications

6

Citations

237

H-Index

6

Active since

2017

Affiliations

University of Basel(Current)

PIQUR Therapeutics (Switzerland)

University of Victoria

Erhan Keleş is an author at University of Basel specializing in drug discovery, pharmacology, and oncology.

ORCID

Publications per year

2017–2022

6

Publications

6

Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas

Sung Hugh Choi, Daniel W. Stuckey, Sara Pignatta et al. · Clinical Cancer Research · 2017 · 56 citations · Full text

, , +17

Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα

Chiara Borsari, Erhan Keleş, Jacob A. McPhail et al. · Journal of the American Chemical Society · 2022 · 55 citations · Full text

, , +17

(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase

Denise Rageot, Thomas Bohnacker, Erhan Keleş et al. · Journal of Medicinal Chemistry · 2019 · 55 citations · Full text

, , +14

Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety

Chiara Borsari, Denise Rageot, Florent Beaufils et al. · ACS Medicinal Chemistry Letters · 2019 · 39 citations · Full text

, , +13

4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

Chiara Borsari, Erhan Keleş, Denise Rageot et al. · Journal of Medicinal Chemistry · 2020 · 22 citations · Full text

, , +14

1–5 of 6